Contact: Joanne Marshall 410-328-8790, firstname.lastname@example.org
Principal Investigator: Mukta Srivastava, MD
Principal Investigator: Gautam Ramani, MD
Principal Investigator: Timm-Michael Dickfeld, MD
Los Angeles, California
Contact: Melissa Minor 323-442-7983, email@example.com
Principal Investigator: Rahul Doshi, MD
Principal Investigator: David Shavelle, MD
Principal Investigator: Andrew Yoon, MD
Contact: Jamie Prior 989-631-2469, firstname.lastname@example.org
Principal Investigator: Andrzej Boguszewski, MD
Principal Investigator: Michael Lauer, MD
Two-Year Data on Breakthrough Treatment to be Presented on Friday, May 18
Menlo Park, Calif. — CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced that clinical trial data from the first-of-its-kind Parachute™ Ventricular Partitioning Device for the treatment of patients with ischemic heart failure will be presented at the 2012 EuroPCR Conference in Paris.
Two-year results from two first-in-human studies of the Parachute system will be presented during a Trials, Registries and Late Breaking Science Hot Line session by Marco Costa, M.D., Ph.D., director of the Interventional Cardiovascular Center and the Research and Innovation Center at the Harrington Heart and Vascular Institute, University Hospitals Case Medical Center, Case Western Reserve University in Cleveland, Ohio.
The session, titled “Percutaneous ventricular restoration therapy in patients with ischemic dilated heart failure: 2-year clinical and echocardiographic outcomes of the first-in-human study of the parachute left ventricle partitioning device” will take place on Friday, May 18 at 9:13 a.m. CET in Room 251.
At 2:10 p.m. CET on Wednesday, May 16, Hüseyin Ince, M.D., Ph.D., professor of Medicine at the University Hospital Rostock in Rostock, Germany, will provide an overview of the Parachute device and Rostock experience during a session titled “Emerging Interventional Technologies for Heart Failure Management” in Room 351.
In addition, two Parachute patient cases will be presented at EuroPCR on Thursday, May 17 in Room 242A:
After a heart attack, many patients experience enlargement of the left ventricle of the heart, causing a decrease in cardiac output that results in heart failure symptoms such as fatigue and shortness of breath. The healthy portion of the heart not affected by the heart attack has to compensate for the loss in output and becomes overloaded over time. Current treatment options for patients whose heart has enlarged are limited. The Parachute device offers the first minimally invasive catheter-based treatment to partition the damaged muscle, excluding the non-functional heart segment from the healthy, functional segment to decrease the overall volume of the left ventricle and restore its geometry and function.
About Heart Failure
Heart failure is a common, debilitating, and potentially deadly condition in which the heart is unable to supply sufficient blood flow to meet the needs of the body. Symptoms of heart failure negatively impact quality of life and include shortness of breath, persistent coughing or wheezing, buildup of excess fluid in body tissues (edema), fatigue, lack of appetite or nausea, impaired thinking, and increased heart rate. More than 20 million people around the world are affected, with approximately six million in the United States, where it is responsible for 1.1 million hospitalizations annually.[i]
About the Parachute™ Ventricular Partitioning DeviceThe first-of-its-kind Parachute Ventricular Partitioning Device is a minimally invasive treatment for patients with heart failure caused by damage to the heart muscle following a heart attack. Clinical data demonstrates improved overall cardiac function and quality of life for patients treated with the Parachute device.
Through a small catheter inserted in the femoral artery, the Parachute implant is deployed in the left ventricle to partition the damaged muscle, excluding the non-functional heart segment from the healthy, functional segment to decrease the overall volume of the left ventricle and restore its geometry and function. This minimally invasive procedure is performed in the catheterization laboratory under conscious sedation.
The Parachute Ventricular Partitioning Device received CE Mark in 2011. In the U.S., the Parachute system is an investigational device limited by federal law to investigational use only and is not available for sale.
About CardioKinetix Inc.
CardioKinetix, based in Menlo Park, Calif., is pioneering the catheter-based Parachute™ Ventricular Partitioning Device for heart failure. Privately held, the company is backed by SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners, Panorama Capital, and H&Q Healthcare Investors. For more information please visit www.cardiokinetix.com.
# # #
[i] Heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation 2012; 125: e2-e220.